inclusion criteria: adult female and male, ≥ 18 years of age at the time of consent medically stable such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment able to understand and comply with study requirements/procedures based on the assessment of the investigator contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies female participants, (a) women of childbearing potential must: have a negative pregnancy test on the day of screening and on day 1; use one highly effective form of birth control for at least 28 days prior to day 1 and agree to continue using one highly effective form of birth control through 60 days following administration of study intervention. capable of giving signed informed consent.

inclusion criteria: adult female and male, ≥ 18 years of age at the time of consent medically stable such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment able to understand and comply with study requirements/procedures based on the assessment of the investigator contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies female participants, (a) women of childbearing potential must: have a negative pregnancy test on the day of screening and on day 1; use one highly effective form of birth control for at least 28 days prior to day 1 and agree to continue using one highly effective form of birth control through 60 days following administration of study intervention. capable of giving signed informed consent.

inclusion criteria: 1. adult female and male, ≥ 18 years of age at the time of consent 2. medically stable such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment 3. able to understand and comply with study requirements/procedures based on the assessment of the investigator 4. contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies 5. female participants, (a) women of childbearing potential must: have a negative pregnancy test on the day of screening and on day 1; use one highly effective form of birth control for at least 28 days prior to day 1 and agree to continue using one highly effective form of birth control through 60 days following administration of study intervention. 6. capable of giving signed informed consent.

inclusion criteria: 1. adult female and male, ≥ 18 years of age at the time of consent 2. medically stable such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment 3. able to understand and comply with study requirements/procedures based on the assessment of the investigator 4. contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies 5. female participants, (a) women of childbearing potential must: have a negative pregnancy test on the day of screening and on day 1; use one highly effective form of birth control for at least 28 days prior to day 1 and agree to continue using one highly effective form of birth control through 60 days following administration of study intervention. 6. capable of giving signed informed consent.